MAIA

#4039
MAIA Biotechnology, Inc. Common Stock
1.3 1 USD
-0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.31
1.32
Jahresspanne
1.16
2.46
Tagesänderung
-1.50%
Monatliche Änderung
-10.27%
6 month change
-12.78%
Jahresänderung
-37.02%
Vorheriger Schlusskurs
1.3 3
Open
1.3 2
Tief
1.3 1
Hoch
1.3 2
Volumen
22
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Quarterly report, Q2 FY2026
MAIA Biotechnology, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
MAIA Biotechnology, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K

MAIA Biotechnology, Inc. current report, Q2 FY2024

Full document

MAIA Biotechnology, Inc. Form 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by MAIA Biotechnology, Inc. (NYSE American: MAIA) on May 24, 2024. The filing details the voting results for director elections and the ratification of the independent auditor. As of the record date of March 28, 2023, there were 20,581,469 shares of common stock issued and outstanding.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting outcomes.

Material Changes and Voting Results

A quorum was established with 14,610,088 shares present, representing approximately 70.98% of outstanding shares. The following matters were approved:

  • Election of Directors: Stockholders re-elected three Class II nominees for three-year terms expiring in 2027.
    • Vlad Vitoc: 10,891,641 votes For; 87,131 Withheld; 3,631,316 Broker Non-Votes.
    • Ramiro Guerrero: 10,573,719 votes For; 405,053 Withheld; 3,631,316 Broker Non-Votes.
    • Cristian Luput: 10,728,696 votes For; 250,076 Withheld; 3,631,316 Broker Non-Votes.
  • Ratification of Auditors: Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
    • Votes For: 14,059,159
    • Votes Against: 10,596
    • Abstain: 540,333

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. For further details on proposals, the filing references the definitive proxy statement dated April 16, 2024.

Key Facts for Investor Verification

  • Verify the re-election of the Class II directors (Vlad Vitoc, Ramiro Guerrero, Cristian Luput) for terms expiring in 2027.
  • Confirm the ratification of Grant Thornton LLP as the independent auditor for the 2024 fiscal year.
  • Note the significant number of broker non-votes (3,631,316) recorded for the director elections.
  • Review the definitive proxy statement filed on April 16, 2024, for detailed background on the proposals.

Nachrichten